- Poster presentation
- Open Access
Juvenile idiopathic arthritis treated with biological therapies
Journal of Translational Medicine volume 10, Article number: P46 (2012)
Biological therapies have dramatically changed the prognosis for children with juvenile idiopathic arthritis (JIA). There are doubts about the possibility of discontinuing treatment once remission is achieved. We focus in this question in our series.
To assess the efficacy and safety of these drugs in our series of patients with JIA.
Materials and methods
We identified 9 children with JIA treated with biologic therapies, and we made a description of our experience.
The mean age was 14.55 ± 5.85, with a female predominance (66.7%). At diagnosis, mean age was 4.94 ± 2.9, and at the beginning of biological treatment of 8.77 ± 2.63. The median time from diagnosis to initiation of biological therapy was 3.94 ± 2.83 years. The disease characteristics are detailed in the table.
All the children had previously received DMARDs (66.6% methotrexate (MTX) and 33.3% MTX and sulfasalazine). Eight of the 9 patients (88.9%) were taking corticosteroids at baseline. Eight received etanercept (ETN) and one Adalimumab (ADA), with good outcomes in all the patients unless 1 that had to switch from ETN to ADA due to inefficacy, and improved after the change. The steroids were suspended in 75% of children (6). Differences between mean values of CRP, ESR, and platelets from baseline to actual moment were statistically significant.
The median biologic time is 4 (1.11) years.
Actually all the children are in remission, two of them (patients 1 and 4) without biological treatment or classic DMARDs (since 5 and 2 years respectively).
None of the children have had significant adverse effects nor required hospitalization from the beginning of therapy.
ETN has proved its efficacy in JIA (regardless of the type of onset), as it has been reported in multiple efficacy and safety studies, including long term studies of up to eight years of continuous therapy.
We present our experience in children treated with up to 11 years, with good outcomes in terms of efficacy and safety in all the patients, and also 2 patients still in remission after 2 and 5 years without treatment.
Giannini EH: Long-term safety and effectiveness of etanercept in children with juvenile idiopathic selected categories of arthritis. Arthritis Rheum. 2009, 60 (9): 2794-2804. 10.1002/art.24777.
Pratsidou-Gertsi P, Trachana M, Pardalos G, Kanakoudi-Tsakalidou F: A follow-up study of juvenile idiopathic arthritis Patients with etanercept discontinued due to Who disease remission. Clin Exp Rheumatol. 2010, 28 (6): 919-22. Epub 2011 Jan 4
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Velloso Feijoo, M.L., Perez, R.M., Montañes, J.U. et al. Juvenile idiopathic arthritis treated with biological therapies. J Transl Med 10 (Suppl 3), P46 (2012). https://doi.org/10.1186/1479-5876-10-S3-P46
- Median Time